DIEBOLD NIXDORF INC (DBD) Fundamental Analysis & Valuation

NYSE:DBD • US2536512021

78.89 USD
-1.46 (-1.82%)
At close: Mar 3, 2026
78.95 USD
+0.06 (+0.08%)
Pre-Market: 3/4/2026, 7:07:20 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DBD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Overall DBD gets a fundamental rating of 4 out of 10. We evaluated DBD against 36 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has an average financial health and profitability rating. DBD is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. DBD Profitability Analysis

1.1 Basic Checks

  • DBD had positive earnings in the past year.
  • In the past year DBD had a positive cash flow from operations.
  • In the past 5 years DBD reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
DBD Yearly Net Income VS EBIT VS OCF VS FCFDBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • With a decent Return On Assets value of 1.36%, DBD is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • With a decent Return On Equity value of 4.57%, DBD is doing good in the industry, outperforming 77.78% of the companies in the same industry.
  • With a decent Return On Invested Capital value of 8.85%, DBD is doing good in the industry, outperforming 69.44% of the companies in the same industry.
  • DBD had an Average Return On Invested Capital over the past 3 years of 5.12%. This is significantly below the industry average of 16.73%.
  • The last Return On Invested Capital (8.85%) for DBD is above the 3 year average (5.12%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.36%
ROE 4.57%
ROIC 8.85%
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
DBD Yearly ROA, ROE, ROICDBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

  • DBD has a better Profit Margin (1.37%) than 66.67% of its industry peers.
  • DBD has a Operating Margin of 7.47%. This is in the better half of the industry: DBD outperforms 75.00% of its industry peers.
  • In the last couple of years the Operating Margin of DBD has grown nicely.
  • The Gross Margin of DBD (25.48%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
Industry RankSector Rank
OM 7.47%
PM (TTM) 1.37%
GM 25.48%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
DBD Yearly Profit, Operating, Gross MarginsDBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. DBD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
  • DBD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DBD Yearly Shares OutstandingDBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
DBD Yearly Total Debt VS Total AssetsDBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

  • DBD has an Altman-Z score of 2.05. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • DBD's Altman-Z score of 2.05 is in line compared to the rest of the industry. DBD outperforms 58.33% of its industry peers.
  • DBD has a debt to FCF ratio of 3.71. This is a good value and a sign of high solvency as DBD would need 3.71 years to pay back of all of its debts.
  • The Debt to FCF ratio of DBD (3.71) is better than 66.67% of its industry peers.
  • DBD has a Debt/Equity ratio of 0.84. This is a neutral value indicating DBD is somewhat dependend on debt financing.
  • DBD's Debt to Equity ratio of 0.84 is in line compared to the rest of the industry. DBD outperforms 41.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 3.71
Altman-Z 2.05
ROIC/WACC0.96
WACC9.25%
DBD Yearly LT Debt VS Equity VS FCFDBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

  • A Current Ratio of 1.36 indicates that DBD should not have too much problems paying its short term obligations.
  • DBD has a Current ratio (1.36) which is in line with its industry peers.
  • DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.89, DBD is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 0.89
DBD Yearly Current Assets VS Current LiabilitesDBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. DBD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.93% over the past year.
  • Measured over the past years, DBD shows a very strong growth in Earnings Per Share. The EPS has been growing by 48.24% on average per year.
EPS 1Y (TTM)40.93%
EPS 3YN/A
EPS 5Y48.24%
EPS Q2Q%183.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.66%

3.2 Future

  • Based on estimates for the next years, DBD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.64% on average per year.
  • DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.76% yearly.
EPS Next Y-9.64%
EPS Next 2Y9.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.28%
Revenue Next 2Y2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
DBD Yearly Revenue VS EstimatesDBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B
DBD Yearly EPS VS EstimatesDBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. DBD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 14.50, DBD is valued correctly.
  • Based on the Price/Earnings ratio, DBD is valued cheaper than 86.11% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of DBD to the average of the S&P500 Index (26.83), we can say DBD is valued slightly cheaper.
  • With a Price/Forward Earnings ratio of 16.05, DBD is valued correctly.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of DBD indicates a somewhat cheap valuation: DBD is cheaper than 66.67% of the companies listed in the same industry.
  • DBD is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.95, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 14.5
Fwd PE 16.05
DBD Price Earnings VS Forward Price EarningsDBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DBD indicates a rather cheap valuation: DBD is cheaper than 91.67% of the companies listed in the same industry.
  • DBD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DBD is cheaper than 80.56% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.25
EV/EBITDA 8.48
DBD Per share dataDBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.3
EPS Next 2Y9.64%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DBD Dividend Analysis

5.1 Amount

  • No dividends for DBD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DBD Fundamentals: All Metrics, Ratios and Statistics

DIEBOLD NIXDORF INC

NYSE:DBD (3/3/2026, 8:04:24 PM)

Premarket: 78.95 +0.06 (+0.08%)

78.89

-1.46 (-1.82%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)02-12
Earnings (Next)05-05
Inst Owners105.4%
Inst Owner Change-2.29%
Ins Owners1.81%
Ins Owner Change-0.17%
Market Cap2.83B
Revenue(TTM)N/A
Net Income(TTM)50.60M
Analysts82.86
Price Target98.6 (24.98%)
Short Float %2.37%
Short Ratio3.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)22.36%
PT rev (3m)22.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)13.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE 14.5
Fwd PE 16.05
P/S 0.77
P/FCF 11.25
P/OCF 10.13
P/B 2.56
P/tB N/A
EV/EBITDA 8.48
EPS(TTM)5.44
EY6.9%
EPS(NY)4.92
Fwd EY6.23%
FCF(TTM)7.01
FCFY8.89%
OCF(TTM)7.79
OCFY9.87%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)N/A
PEG (5Y)0.3
Graham Number61.47
Profitability
Industry RankSector Rank
ROA 1.36%
ROE 4.57%
ROCE 11.2%
ROIC 8.85%
ROICexc 9.91%
ROICexgc 29.15%
OM 7.47%
PM (TTM) 1.37%
GM 25.48%
FCFM 6.82%
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 3.71
Debt/EBITDA 2.28
Cap/Depr 20.59%
Cap/Sales 0.75%
Interest Coverage 2.89
Cash Conversion 68.06%
Profit Quality 497.23%
Current Ratio 1.36
Quick Ratio 0.89
Altman-Z 2.05
F-Score7
WACC9.25%
ROIC/WACC0.96
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.93%
EPS 3YN/A
EPS 5Y48.24%
EPS Q2Q%183.51%
EPS Next Y-9.64%
EPS Next 2Y9.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.66%
Revenue Next Year2.28%
Revenue Next 2Y2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.55%
EBIT Next 3Y13.91%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%

DIEBOLD NIXDORF INC / DBD FAQ

What is the fundamental rating for DBD stock?

ChartMill assigns a fundamental rating of 4 / 10 to DBD.


Can you provide the valuation status for DIEBOLD NIXDORF INC?

ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.


What is the profitability of DBD stock?

DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.


What is the financial health of DIEBOLD NIXDORF INC (DBD) stock?

The financial health rating of DIEBOLD NIXDORF INC (DBD) is 4 / 10.


How sustainable is the dividend of DIEBOLD NIXDORF INC (DBD) stock?

The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.